GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » Inventory-to-Revenue

Biocept (Biocept) Inventory-to-Revenue : 1.07 (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Biocept Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biocept's Average Total Inventories for the quarter that ended in Jun. 2023 was $0.63 Mil. Biocept's Revenue for the three months ended in Jun. 2023 was $0.59 Mil. Biocept's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 1.07.

Biocept's Inventory-to-Revenue for the quarter that ended in Jun. 2023 declined from Mar. 2023 (1.09) to Mar. 2023 (1.07)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biocept's Days Inventory for the three months ended in Jun. 2023 was 22.45.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biocept's Inventory Turnover for the quarter that ended in Jun. 2023 was 4.06.


Biocept Inventory-to-Revenue Historical Data

The historical data trend for Biocept's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Inventory-to-Revenue Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.12 0.05 0.04 0.07

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 2.06 - 1.09 1.07

Competitive Comparison of Biocept's Inventory-to-Revenue

For the Diagnostics & Research subindustry, Biocept's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept's Inventory-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biocept's Inventory-to-Revenue falls into.



Biocept Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biocept's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Inventory-to-Revenue (A: Dec. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2021 ) + Total Inventories (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )
=( (2.651 + 0.757) / 2 ) / 25.858
=1.704 / 25.858
=0.07

Biocept's Inventory-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue (Q: Jun. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Mar. 2023 ) + Total Inventories (Q: Jun. 2023 )) / count ) / Revenue (Q: Jun. 2023 )
=( (0.704 + 0.551) / 2 ) / 0.589
=0.6275 / 0.589
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocept  (OTCPK:BIOCQ) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biocept's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2023 )/Cost of Goods Sold (Q: Jun. 2023 )*Days in Period
=0.6275/2.55*365 / 4
=22.45

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biocept's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2023 ) / Average Total Inventories (Q: Jun. 2023 )
=2.55 / 0.6275
=4.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocept Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biocept's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (Biocept) Business Description

Traded in Other Exchanges
N/A
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Executives
Robert Walsh officer: VP, Controller 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock director C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand officer: Chief Operations Officer C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor officer: Sr. V.P., General Counsel C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale director, officer: EXECUTIVE CHAIRMAN 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales director C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein director 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan officer: Chief Med Off & Med. Director 2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory officer: Sr. VP Corp. Development C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick officer: SVP, Chief Commercial Officer 2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry officer: Sr VP Comm. Operations
Marsha Alpert Chandler director 7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall director, officer: CEO AND PRESIDENT 4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy officer: CFO, Sr V.P. Operations & Sec. 5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121